Martin Wabitsch

Dr. Martin Wabitsch

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
NLNatalie Lister
Natalie Lister
LBLouise A. Baur
Louise A. Baur
JFJanine F. Felix
Janine F. Felix
AHAndrew Hill
Andrew Hill
CMClaude Marcus
Claude Marcus
MWMartin Wabitsch
Martin Wabitsch

1 December 2020 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
KCKarine Clément
Karine Clément
EAErica van Den Akker
Erica van Den Akker
JAJesús Argente
Jesús Argente
ABAllison Bahm
Allison Bahm
WCWendy K Chung
Wendy K Chung
GYGoujun Yuan
Goujun Yuan

24 August 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
Yvan VandenplasYvan Vandenplas
Yvan Vandenplas
BBBernard Berger
Bernard Berger
VCVirgilio Paolo Carnielli
Virgilio Paolo Carnielli
JKJanusz Książyk
Janusz Książyk
HLHanna Lagström
Hanna Lagström
MWMartin Wabitsch
Martin Wabitsch
The authors reviewed the published evidence on the presence of oligosaccharides in human milk (HMO) and their benefits in in vitro and in vivo studies. The still limited data of trials evaluating the effect of mainly 2′-fucosyllactose (2′-FL) on the addition of some of HMOs to infant formula were also reviewed. PubMed was searched from January 1990 to April 2018. The amount of HMOs in mother’s milk is a dynamic process as it changes over time. Many factors, such as duration of lactation, environmental, and genetic factors, influence the amount of HMOs. HMOs may support immune function development and provide protection against infectious diseases directly through the interaction of the gut epithelial cells or indirectly through the modulation of the gut microbiota, including the stimulation of the bifidobacteria. The limited clinical data suggest that the addition of HMOs to infant formula seems to be safe and well tolerated, inducing a normal growth and suggesting a trend towards health benefits. HMOs are one of the major differences between cow’s milk and human milk, and available evidence indicates that these components do have a health promoting benefit. The addition of one or two of these components to infant formula is safe, and brings infant formula closer to human milk. More prospective, randomized trials in infants are need to evaluate the clinical benefit of supplementing infant formula with HMOs.

1 January 2008 in Obesity Facts
Verified
Journal Article
Closed access
PDF file
PFPamela Fischer-Posovszky
Pamela Fischer-Posovszky
FNFelicity S. Newell
Felicity S. Newell
MWMartin Wabitsch
Martin Wabitsch
HTHans E. Tornqvist
Hans E. Tornqvist
The human Simpson-Golabi-Behmel syndrome (SGBS) preadipocyte cell strain provides a unique and useful tool for studies of human adipocyte biology. The cells originate from an adipose tissue specimen of a patient with SGBS. They are neither transformed nor immortalized, and provide an almost unlimited source due to their ability to proliferate for up to 50 generations with retained capacity for adipogenic differentiation. So far, the cells have been used for a number of studies on adipose differentiation, adipocyte glucose uptake, lipolysis, apoptosis, regulation of expression of adipokines, and protein translocation. The cells are efficiently differentiated in the presence of PPARγagonists and in the absence of serum and albumin. SGBS adipocytes respond to insulin stimulation by increasing glucose uptake several-fold (EC50 approximately 100 pmol/l), and by very effectively inhibiting (IC50 approximately 10 pmol/l) catecholamine-stimulated lipolysis.

31 January 2014 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MWMartin Wabitsch
Martin Wabitsch
AMAnja Moss
Anja Moss
KKKatrin Kromeyer-Hauschild
Katrin Kromeyer-Hauschild
Surveys performed in the past 10 to 15 years show a yet unexplained stabilization or decline in prevalence rates of childhood obesity in developed countries. The projected continuous increase in obesity prevalence throughout future decades seems not to occur at present. Apparently, saturation has been reached, which might be related to societal adjustments. Hence, we postulate a cumulative effect of public health programs for obesity prevention resulting, for example, in an increase in physical activity, and a decline in television viewing and in the consumption of sugar-sweetened soft drinks by children. Effective public health programs are urgently needed for developing countries, where obesity rates in children still continued to increase during the past decade.

29 January 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
WXWenmin Xia
Wenmin Xia
PVPreethi Veeragandham
Preethi Veeragandham
YCYu Cao
Yu Cao
YXYayun Xu
Yayun Xu
TRTorrey E. Rhyne
Torrey E. Rhyne
ASAlan R. Saltiel
Alan R. Saltiel
Mitochondrial dysfunction is a characteristic trait of human and rodent obesity, insulin resistance and fatty liver disease. Here we show that high-fat diet (HFD) feeding causes mitochondrial fragmentation in inguinal white adipocytes from male mice, leading to reduced oxidative capacity by a process dependent on the small GTPase RalA. RalA expression and activity are increased in white adipocytes after HFD. Targeted deletion of RalA in white adipocytes prevents fragmentation of mitochondria and diminishes HFD-induced weight gain by increasing fatty acid oxidation. Mechanistically, RalA increases fission in adipocytes by reversing the inhibitory Ser637 phosphorylation of the fission protein Drp1, leading to more mitochondrial fragmentation. Adipose tissue expression of the human homolog of Drp1, DNM1L, is positively correlated with obesity and insulin resistance. Thus, chronic activation of RalA plays a key role in repressing energy expenditure in obese adipose tissue by shifting the balance of mitochondrial dynamics toward excessive fission, contributing to weight gain and metabolic dysfunction.